Background
Methods
Discussion
Anabolic-androgenic steroids
Acute kidney injury (AKI)
Chronic kidney diseases (CKD)
Progression of CKD
Glomerular toxicity
Dose & Duration | Subjects | Type of study | Main results | Reference |
---|---|---|---|---|
50 mg/day dihydrotestosterone intraperitoneally for 10 days | Rats | Experimental | - Increase in blood pressure, and proximal tubule volume reabsorption - Decrease in serum angiotensin II level - No change in glomerular filtration rate | Quan et al. 2004 [29] |
500 μg/kg/day testosterone propionate intramuscularly for 2 weeks | Castrated male and oophorectomized female rats with obstructive renal injury | Experimental | Increase in TNF-α production and pro-apoptotic and pro-fibrotic signaling leading to increased apoptotic cell death, tubulointerstitial fibrosis, and renal dysfunction | Metcalfeet al 2008 [28] |
0.75 or 2.0 mg/day dihydrotestosterone as subcutaneous implants for 14 weeks | Castrated diabetic male rats | Experimental | - Low doses attenuated castration-associated increases in urine albumin excretion, glomerulosclerosis, and tubulointerstitial fibrosis - High doses exacerbated castration-associated increases in urine albumin excretion, glomerulosclerosis, and tubulointerstitial fibrosis | Xu et al. 2009 [56] |
Testosterone implants (20 mg/capsule) changed every 2 weeks | Hypertensive rats on a high sodium diet | Experimental | - Increase in blood pressure & renal sodium reabsorption - Increase in glomerulosclerosis | Liu&Ely 2011 [33] |
Single dose of testosterone (12.5 mg/pellet) orally | Female estrogen receptor knockout mice | Experimental | Inducing podocyte apoptosis by androgen receptor activation, independent of the TGF-β1 signaling pathway | Doublier et al. 2011 [48] |
Combination of 0.75 mg/day dihydrotestosterone as subcutaneous implants and 0.15 mg/kg/day anastrozole orally for 12 weeks | Diabetic male rats | Experimental | - Attenuating albuminuria, glomerulosclerosis, and tubulointerstitial fibrosis - Decrease in the density of renal cortical CD68-positive cells - Decrease in the expression of transforming growth factor-β, collagen type IV, TNF-α, and IL-6 | Manigrasso et al. 2012 [55] |
Case 1: Not defined | Case 1: 21-year-old male athlete | Case report and case series | - Arterial hypertension, oliguria, leukocyturia, hematuria and proteinuria, increase in serum urea and creatinine - Moderate interstitial inflammatory infiltrate with eosinophils, interstitial edema, calcium deposits, and mild acute tubular necrosis | Daher et al. 2009 [20] |
Case 2: Not defined | Case 2: 30-year-old male bricklayer | - Increase in serum urea and creatinine, hematuria and proteinuria - Mild interstitial lymphmononuclear inflammatory infiltrate with eosinophils without remarkable tubular abnormalities | ||
Case series: Not defined | Case series: Males & Females aged between 21 and 63 years | - Interstitial nephritis and hypercalcemia secondary to vitamin D intoxication caused acute kidney injury | ||
At least one anabolic steroid (e.g., testosterone 500 mg twice weekly) intramuscularly for several months | 10 body builders aged between 28 and 49 years | Case series | - Proteinuria, renal insufficiency, and nephrotic syndrome - Focal segmental glomerulosclerosis, tubular atrophy, and interstitial fibrosis | Herlitz et al. 2010 [57] |
Not defined | 38-year-old man | Case report | - High serum creatinine, high serum urea, low hemoglobin level - Intrinsic renal parenchymal and focal segmental glomerulosclerosis | Harrington et al. 2011 [58] |
- Nandrolone intramuscular injection 400 mg twice per week for 6 weeks - Testosterone intramuscular injection 400 mg once per week for 6 weeks | 41-year-old male bodybuilder | Case report | Acute kidney injury with the pathology of diffuse acute tubular injury due to bile acid nephropathy with the pathology of tubular bile acid casts | Luciano et al. 2014 [19] |
Case 1: Stanozolol intramuscular injection 10 mg three times per week for 5 weeks Case 2: Stanozolol intramuscular injection 1 mg three times per week for 6 weeks | Case 1: 30-year-old male amateur bodybuilder Case 2: 43-year-old male amateur bodybuilder | Case report | Bile cast nephropathy due to cholestatic jaundice characterized by acute tubular epithelial cell damage along with increased serum creatinine and oliguria | Tabatabaee et al. 2015 [23] |
Oxandrolone, boldenone undecyclenate, stanozolol, and trenabol (with not-defined daily dose and duration of treatment) | 28-year-old male bodybuilder | Case report | Acute kidney injury in the setting of severe cholestatic jaundice with the pathology of bile inclusions within tubular cells and interstitial edema | Alkhunaizi et al. 2016 [24] |
Growth hormone
Growth hormone sources in the body, its biological effects, and general safety
Growth hormone safety on renal functions
Dose & Duration | Subjects | Type of study | Main results | Reference |
---|---|---|---|---|
2.5, 5, 10, and 20 lU/kg/day subcutaneously for 4–60 days | Female rats | Experimental | - Dose-dependent increase in renal weight - No change in kidney dry weight/body weight ratio - Increase in renal glomerular and tubular cell proliferation and renal DNA/protein ratio | Mehls et al. 1993 [86] |
0.025, 0.1, and 1 IU/kg/day subcutaneously for 14 weeks | Male and female dogs | Experimental | - Increase in body weight gain and kidney weights - Glomerular deposits, mesangial thickening, and very slight cellular infiltration in glomeruli - Increase in the renal glomerular area - Glomerular basal lamina thickening - Increase in mesangial matrix | Molon-Noblot et al. 2000 [87] |
5–10 mg/day for 3–9 days | 2 patients with hypopituitarism, 1 with cirrhosis of the liver and 2 with chronic nephritis and uremia | Case report | - Decrease in plasma urea level and urea excretion - Prompt increase in creatinine clearance and phosphorus reabsorption | Gershberg 1960 [80] |
More than 400 mg/week testosterone proprionate and/or nandrolone deconate intramuscularly | 4 body builders aged between 20 and 26 years | Case report | - Increase in serum creatinine and decreased in eGFR - Development of acute tubular necrosis | Almukhtar et al. 2015 [22] |
50 ng/kg/min as an infusion for 2 h | Healthy men | Pilot clinical trial | - Decrease in renal plasma flow - No change in GFR | Parving et al. 1978 [81] |
2 IU in the morning and 4 IU in the evening subcutaneously for 1 week | Healthy men | Pilot clinical trial | - Increase in GFR and renal plasma flow - No significant change in kidney size and urinary excretion rates of albumin and β2-microglobulin | Christiansen et al. 1981 [93] |
0.125 IU/kg per week subcutaneously for the first 4 weeks and 0.25 IU/kg per week for the subsequent 5 months | Growth hormone deficient adults | Double-blind, placebo-controlled, cross-over clinical trial | - No change in GFR and renal plasma flow - No effect on kidney size | Riedl et al. 1995 [82] |
0·02 IU/kg/day (or 7 μg/kg/day) subcutaneously for 10 months | Adults with childhood onset GH deficiency | Pilot clinical trial | - Increase in left ventricular-mass index and kidney length - No abnormalities or change in the urine analysis | Link et al. 2001 [94] |
6 IU/m2 per day subcutaneously for 6 days | Healthy volunteer males | Randomized, cross-over clinical trial | - Increase in the plasma renin - Increase in distal tubule sodium and water reabsorption - Decrease in mean 24-h urinary output and mean 24-h urinary sodium excretion | Hansen et al. 2001 [99] |